Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients

Acta Oncologica

Volumn 41, Issue 5, 2002, Pages 463-470

  Røtterud, Ranveig ^a   Pettersen, Erik O ^a   Berner, Aasmund ^a   Holm, Ruth ^a   Rune Olsen, Dag ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY; CELL CULTURE; IMMUNOLOGY; PATIENT TREATMENT; PROTEINS; RADIOTHERAPY; TUMORS;

CELL CYCLE;

ONCOLOGY;

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BIOPSY;

CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL CYCLE PROTEINS; CREATININE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; CYSTECTOMY; HEMOGLOBINS; HUMANS; LIFE TABLES; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RADIATION TOLERANCE; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 17344374596     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602320405069     Document Type: Article

References (35)

1. Sengelov L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol 1999; 52: 1-14.
2. West CM, Keng PC, Sutherland RM. Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys 1988; 14: 1213-9.
3. Quiet CA, Weichselbaum RR, Grdina DJ. Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int J Radiat Oncol Biol Phys 1991; 20: 733-8.
4. Biade S, Stobbe CC, Chapman JD. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 1997; 147: 416-21.
5. Hill AA, Wan F, Acheson DK, Skarsgard LD. Lack of correlation between G1 arrest and radiation age-response in three synchronized human tumour cell lines. Int J Radiat Biol 1999; 75: 1395-408.
6. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-4.
7. Thullberg M, Bartkova J, Khan S, et al. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. FEBS Lett 2000; 470: 161-6.
8. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999; 50: 401-23.
9. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
10. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847-62.
11. Huschtscha LI, Reddel RR. p16 (INK4a) and the control of cellular proliferative life span. Carcinogenesis 1999; 20: 921- 6.
12. Korkolopoulou P, Christodoulou P, Lazaris A, et al. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: A multivariate analysis including p53 expression and proliferation markers. Eur Urol 2001; 39: 167-77.
13. Gartel AL, Tyner AL. Transcriptional regulation of the p21 WAF1/CIP1 gene. Exp Cell Res 1999; 246: 280-9.
14. Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227: 25-41.
15. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313-23.
16. Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: A review. Radiother Oncol 1994; 31: 1-13.
17. Aldridge DR, Radford IR. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 1998; 58: 2817-24.
18. Maity A, Kao GD, Muschel RJ, McKenna WG. Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 1997; 37: 639-53.
19. Rotterud R, Berner A, Holm R, Skovlund E, Fossa SD. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. Br J Urol Int 2001; 88: 202-8.
20. Mostofi FK. Introduction. In: Mostofi FK, Sobin LH, Torloni H, eds. Histological Typing of Urinary Bladder Tumours. 1st Ed. Geneva: World Health Organization, 1973: 17.
21. Fossa SD, Roberts T, Olsen DR. Radiotherapy in the management of bladder cancer. Eur Update Ser 1997; 6: 80-5.
22. Akimoto T, Seong J, Hunter NR, Buchmiller L, Mason K, Milas L. Association of increased radiocurability of murine carcinonas with low constitutive expression of p21 WAF1/CIP1 protein. Int J Radiat Oncol Biol Phys 1999; 44: 413-9.
23. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6.
24. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997; 57: 4703-6.
25. Kokunai T, Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn J Cancer Res 1999; 90: 638-46.
26. Song S, Lambert PF. Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. Am J Pathol 1999; 155: 1121-7.
27. Hsiao M, Tse V, Carmel J, et al. Functional expression of human p21 WAF1/CIP1 gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem Biophys Res Commun 1997; 233: 329-35.
28. Osen I, Fosså SD, Majak B, Rotterud R, Berner A. Prognostic factors in muscle invasive bladder cancer treated with radiotherapy. Br J Urol 1998; 81: 862-9.
29. Ahrendt SA, Brown HM, Komorowski RA, et al. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 2000; 128: 520-30.
30. Oka K, Suzuki Y, Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: Radiotherapeutic effect and prognosis. Cancer 2000; 88: 2766-73.
31. Miyakoshi J, Kitagawa K, Yamagishi N, Ohtsu S, Day RS, Takebe H. Increased radiosensitivity of p16 gene-deleted human glioma cells after transfection with wild-type p16 gene. Jpn J Cancer Res 1997; 88: 34-8.
32. Fu XY, Zhang SW, Ran RQ, Shen ZH, Gu JX, Cao SL. Restoration of the p16 gene is related to increased radiosensitivity of p16-deficient lung adenocarcinoma cell lines. J Cancer Res Clin Oncol 1998; 124: 621-6.
33. Chow LS, Wang X, Kwong DL, Sham JS, Tsao SW, Nicholls JM. Effect of p16INK4a on chemosensitivity in nasopharyngeal carcinoma cells. Int J Oncol 2000; 17: 135-40.
34. Matsumura Y, Yamagishi N, Miyakoshi J, Imamura S, Takebe H. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett 1997; 115: 91-6.
35. Valenzuela MT, Nunez MI, Villalobos M, et al. A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation. Int J Cancer 1997; 72: 307-12.